Le Journal

Chutes & Ladders—Gilead abruptly parts ways with general counsel

GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement

Roche inks $200M+ licensing pact for Freenome's cancer screening blood tests
Roche will make a new $75 million equity investment in Freenome, toward the goal of developing blood testing kits for markets outside the U.S.

FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process

CDC instructs researchers to end all monkey studies by year-end: Science

In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation
Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of biopharma respondents said they were concerned about the FDA’s ability to function.

'People are getting used to it': Global uncertainties can't dampen upbeat Jefferies conference
No matter who Fierce could pull aside for a quick coffee at the conference, the general view was of a renewed sense of cautious optimism.

Bayer's asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class
Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past two years.

Magifique Maison D HOTES 25 PIECES OUVEILLAN

Somptueuse maison de MaItre vue 14 PIECES 350 Metsup2; BISINCHI

VILLA CONTEMPORAINE 10 PIECES PLAIN PIED VUE MER ANTIBES

